Ziyong Liu, Tao Ma, Jinfang Li, Wei Ren, Zhixin Zhang
{"title":"IL13RA2通过激活糖酵解和Wnt/β-catenin信号通路促进婴儿血管瘤的进展。","authors":"Ziyong Liu, Tao Ma, Jinfang Li, Wei Ren, Zhixin Zhang","doi":"10.32604/or.2024.048315","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown.</p><p><strong>Materials and methods: </strong>IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot.</p><p><strong>Results: </strong>IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, which was confirmed with a glycolysis inhibitor. Specifically, IL13RA2 interacted with β-catenin and activated the Wnt/β-catenin pathway in HemECs, which were involved in the above-mentioned effects of IL13RA2.</p><p><strong>Conclusions: </strong>These findings revealed that targeting IL13RA2 is a potential therapeutic approach for IH.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 9","pages":"1453-1465"},"PeriodicalIF":2.0000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361910/pdf/","citationCount":"0","resultStr":"{\"title\":\"IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.\",\"authors\":\"Ziyong Liu, Tao Ma, Jinfang Li, Wei Ren, Zhixin Zhang\",\"doi\":\"10.32604/or.2024.048315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown.</p><p><strong>Materials and methods: </strong>IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot.</p><p><strong>Results: </strong>IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, which was confirmed with a glycolysis inhibitor. Specifically, IL13RA2 interacted with β-catenin and activated the Wnt/β-catenin pathway in HemECs, which were involved in the above-mentioned effects of IL13RA2.</p><p><strong>Conclusions: </strong>These findings revealed that targeting IL13RA2 is a potential therapeutic approach for IH.</p>\",\"PeriodicalId\":19537,\"journal\":{\"name\":\"Oncology Research\",\"volume\":\"32 9\",\"pages\":\"1453-1465\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361910/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32604/or.2024.048315\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.048315","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:白细胞介素13受体亚基α2(IL13RA2)在许多癌症的发展过程中起着至关重要的作用。然而,IL13RA2在婴儿血管瘤(IH)中的作用尚不清楚:采用Western印迹、qRT-PCR和免疫荧光分析了IL13RA2在IH组织中的表达。通过CCK-8、菌落形成、细胞凋亡、伤口愈合、小管形成、Transwell和Western blot检测IL13RA2被敲除或过表达后在血管瘤衍生内皮细胞(HemECs)中的作用:结果:IL13RA2在IH组织中表达上调。结果:IL13RA2 在 IH 组织中表达上调,IL13RA2 的过表达促进了血液活细胞的增殖、迁移和侵袭,并诱导了糖酵解,糖酵解抑制剂证实了这一点。具体而言,IL13RA2与β-catenin相互作用,激活了血红素细胞中的Wnt/β-catenin通路,而Wnt/β-catenin通路参与了IL13RA2的上述作用:这些发现揭示了以IL13RA2为靶点是治疗IH的一种潜在方法。
IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.
Background: Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown.
Materials and methods: IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot.
Results: IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, which was confirmed with a glycolysis inhibitor. Specifically, IL13RA2 interacted with β-catenin and activated the Wnt/β-catenin pathway in HemECs, which were involved in the above-mentioned effects of IL13RA2.
Conclusions: These findings revealed that targeting IL13RA2 is a potential therapeutic approach for IH.
期刊介绍:
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.